Your browser doesn't support javascript.
loading
Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting.
Greenberg, Lauren; Ryom, Lene; Neesgaard, Bastian; Miró, Jose M; Dahlerup Rasmussen, Line; Zangerle, Robert; Grabmeier-Pfistershammer, Katharina; Günthard, Huldrych F; Kusejko, Katharina; Smith, Colette; Mussini, Cristina; Menozzi, Marianna; Wit, Ferdinand; Van Der Valk, Marc; d'Arminio Monforte, Antonella; De Wit, Stéphane; Necsoi, Coca; Pelchen-Matthews, Annegret; Lundgren, Jens; Peters, Lars; Castagna, Antonella; Muccini, Camilla; Vehreschild, Jörg Janne; Pradier, Christian; Bruguera Riera, Andreu; Sönnerborg, Anders; Petoumenos, Kathy; Garges, Harmony; Rogatto, Felipe; Dedes, Nikos; Bansi-Matharu, Loveleen; Mocroft, Amanda.
Afiliação
  • Greenberg L; Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, United Kingdom.
  • Ryom L; CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Neesgaard B; CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Miró JM; Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain.
  • Dahlerup Rasmussen L; Department of Infectious Diseases, Odense University Hospital, Odense, Denmark.
  • Zangerle R; Austrian HIV Cohort Study (AHIVCOS), Medizinische Universität Innsbruck, Innsbruch, Austria.
  • Grabmeier-Pfistershammer K; Medical University Vienna, Vienna, Austria.
  • Günthard HF; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
  • Kusejko K; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Smith C; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
  • Mussini C; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Menozzi M; Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, United Kingdom.
  • Wit F; Modena HIV Cohort, Università degli Studi di Modena, Modena, Italy.
  • Van Der Valk M; Azienda Ospedaliero Universitaria di Modena, Modena, Italy.
  • d'Arminio Monforte A; AIDS Therapy Evaluation in the Netherlands Cohort (ATHENA), HIV Monitoring Foundation, Amsterdam, the Netherlands.
  • De Wit S; AIDS Therapy Evaluation in the Netherlands Cohort (ATHENA), HIV Monitoring Foundation, Amsterdam, the Netherlands.
  • Necsoi C; Department of Infectious Diseases, Amsterdam Infection and Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Pelchen-Matthews A; Italian Cohort Naive Antiretrovirals (ICoNA), ASST Santi Paolo e Carlo, Milano, Italy.
  • Lundgren J; CHU Saint-Pierre, Infectious Diseases, Saint-PIerre University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
  • Peters L; CHU Saint-Pierre, Centre de Recherche en Maladies Infectieuses a.s.b.l., Brussels, Belgium.
  • Castagna A; Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, United Kingdom.
  • Muccini C; CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Vehreschild JJ; CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Pradier C; San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, Milano, Italy.
  • Bruguera Riera A; San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, Milano, Italy.
  • Sönnerborg A; Medical Department 2, Hematology/Oncology, University Hospital of Frankfurt, Frankfurt, Germany.
  • Petoumenos K; Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
  • Garges H; Nice HIV Cohort, Université Côte d'Azur et Centre Hospitalier Universitaire, Nice, France.
  • Rogatto F; PISCIS Cohort Study, Centre Estudis Epidemiologics de ITS i VIH de Catalunya, Badalona, Spain.
  • Dedes N; Swedish InfCare HIV Cohort, Karolinska University Hospital, Stockholm, Sweden.
  • Bansi-Matharu L; The Australian HIV Observational Database (AHOD), UNSW, Sydney, Australia.
  • Mocroft A; ViiV Healthcare, Research Triangle Park, North Carolina, USA.
Open Forum Infect Dis ; 9(3): ofac029, 2022 Mar.
Article em En | MEDLINE | ID: mdl-35198646
BACKGROUND: Limited data exist examining the association between incident cancer and cumulative integrase inhibitor (INSTI) exposure. METHODS: Participants were followed from baseline (latest of local cohort enrollment or January 1, 2012) until the earliest of first cancer, final follow-up, or December 31, 2019. Negative binomial regression was used to assess associations between cancer incidence and time-updated cumulative INSTI exposure, lagged by 6 months. RESULTS: Of 29 340 individuals, 74% were male, 24% were antiretroviral treatment (ART)-naive, and median baseline age was 44 years (interquartile range [IQR], 36-51). Overall, 13 950 (48%) individuals started an INSTI during follow-up. During 160 657 person-years of follow-up ([PYFU] median 6.2; IQR, 3.9-7.5), there were 1078 cancers (incidence rate [IR] 6.7/1000 PYFU; 95% confidence interval [CI], 6.3-7.1). The commonest cancers were non-Hodgkin lymphoma (n = 113), lung cancer (112), Kaposi's sarcoma (106), and anal cancer (103). After adjusting for potential confounders, there was no association between cancer risk and INSTI exposure (≤6 months vs no exposure IR ratio: 1.15 [95% CI, 0.89-1.49], >6-12 months; 0.97 [95% CI, 0.71-1.32], >12-24 months; 0.84 [95% CI, 0.64-1.11], >24-36 months; 1.10 [95% CI, 0.82-1.47], >36 months; 0.90 [95% CI, 0.65-1.26] [P = .60]). In ART-naive participants, cancer incidence decreased with increasing INSTI exposure, mainly driven by a decreasing incidence of acquired immune deficiency syndrome cancers; however, there was no association between INSTI exposure and cancer for those ART-experienced (interaction P < .0001). CONCLUSIONS: Cancer incidence in each INSTI exposure group was similar, despite relatively wide CIs, providing reassuring early findings that increasing INSTI exposure is unlikely to be associated with an increased cancer risk, although longer follow-up is needed to confirm this finding.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Incidence_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Incidence_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article